Evidence for the Interplay between Inflammation and Clotting System in the Pathogenetic Chain of Pulmonary Embolism: A Potential Therapeutic Target to Prevent Multi-organ Failure and Residual Thrombotic Risk

Pulmonary Embolism (PE) is a complex multifactorial syndrome characterized by a wide spectrum of symptoms, representing the third most common acute cardiovascular syndrome after myocardial infarction and stroke. While the diagnosis of PE has become routine clinical practice, its risk stratification remains challenging. Prediction of clinical outcomes of different PE phenotypes is a growing area of research exploring the role of biomarkers.